Gabapentin (All indications) updated on 04-22-2025

Preterm (< 37 weeks)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S10095
R36744		 Coste (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020 Gestational age at birth (< 37 WA) during pregnancy (anytime or not specified) retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: No 2.08 [1.48;2.93] C
excluded (control group) 		46/378   182/2,916 228 378
ref
S8517
R28087		 Coste (Controls unexposed, NOS) (Mixed indications), 2020 Gestational age at birth (< 37 WA) during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 2.46 [1.81;3.35] C 46/378   91,255/1,710,441 91,301 378
ref
S8490
R27880		 Miškov (Controls exposed to Lamotrigine, sick), 2016 Premature deliveries during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick excluded Adjustment: No 12.00 [0.53;273.05] C
excluded (control group) 		1/2   2/26 3 2
ref
S8491
R27885		 Miškov (Controls unexposed, disease free), 2016 Premature deliveries during pregnancy (anytime or not specified) prospective cohort unexposed, disease free excluded Adjustment: No 31.00 [1.63;589.49] C
excluded (control group) 		1/2   4/128 5 2
ref
S8492
R27891		 Miškov (Controls unexposed, sick), 2016 Premature deliveries during pregnancy (anytime or not specified) prospective cohort unexposed, sick Adjustment: No 21.00 [0.27;1646.32] C 1/2   0/4 1 2
ref
S8485
R27852		 Arkilo, 2015 Premature delivery during pregnancy (anytime or not specified) retrospective cohort exposed to other treatment, sick Adjustment: No 5.86 [0.10;346.64] C 0/1   3/24 3 1
ref
S8513
R28058		 Kilic (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 Preterm (< 37 weeks) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 1.37 [0.66;2.86] C
excluded (control group) 		9/72   83/880 92 72
ref
S8514
R28061		 Kilic (Controls unexposed NOS) (Mixed indications), 2014 Preterm (< 37 weeks) during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) excluded Adjustment: No 2.50 [1.40;4.60]
excluded (control group) 		9/72   33,974/676,834 33,983 72
ref
S8515
R28064		 Kilic (Controls unexposed, sick) (Mixed indications), 2014 Preterm (< 37 weeks) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, sick Adjustment: No Controls: epilepsy indication 1.83 [0.90;3.71] C 9/72   383/5,296 392 72
ref
Total 4 studies 2.38 [1.79;3.15] 91,697 453
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Coste (Controls unexposed, NOS) (Mixed indications), 2020Coste, 2020 1 2.46[1.81; 3.35]91,30137883%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Miškov (Controls unexposed, sick), 2016Miškov, 2016 2 21.00[0.27; 1646.32]120%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: criticalROB mesure: moderateROB reporting: moderate Arkilo, 2015Arkilo, 2015 5.86[0.10; 346.64]310%ROB confusion: criticalROB selection: criticalROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Kilic (Controls unexposed, sick) (Mixed indications), 2014Kilic, 2014 3 1.83[0.90; 3.71]3927216%ROB confusion: criticalROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Total (4 studies) I2 = 0% 2.38[1.79; 3.15]91,6974530.550.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, NOS) (Mixed indications; 2: Controls unexposed, sick; 3: Controls unexposed, sick) (Mixed indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 2.38[1.79; 3.15]91,6974530%NACoste (Controls unexposed, NOS) (Mixed indications), 2020 Miškov (Controls unexposed, sick), 2016 Arkilo, 2015 Kilic (Controls unexposed, sick) (Mixed indications), 2014 4 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 2.46[1.81; 3.35]91,301378 -NACoste (Controls unexposed, NOS) (Mixed indications), 2020 1 unexposed, sickunexposed, sick 2.31[0.57; 9.35]3937415%NAMiškov (Controls unexposed, sick), 2016 Kilic (Controls unexposed, sick) (Mixed indications), 2014 2 exposed to other treatment, sickexposed to other treatment, sick 5.86[0.10; 346.64]31 -NAArkilo, 2015 1 Tags Adjustment   - No  - No 2.38[1.79; 3.15]91,6974530%NACoste (Controls unexposed, NOS) (Mixed indications), 2020 Miškov (Controls unexposed, sick), 2016 Arkilo, 2015 Kilic (Controls unexposed, sick) (Mixed indications), 2014 4 Controls   - epilepsy indication  - epilepsy indication 1.83[0.90; 3.71]39272 -NAKilic (Controls unexposed, sick) (Mixed indications), 2014 1 All studiesAll studies 2.38[1.79; 3.15]91,6974530%NACoste (Controls unexposed, NOS) (Mixed indications), 2020 Miškov (Controls unexposed, sick), 2016 Arkilo, 2015 Kilic (Controls unexposed, sick) (Mixed indications), 2014 40.550.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-5.26.12.6700.000Coste (Controls unexposed, NOS) (Mixed indications), 2020Miškov (Controls unexposed, sick), 2016Arkilo, 2015Kilic (Controls unexposed, sick) (Mixed indications), 2014

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 8513, 8514, 8490, 8491, 10095

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 2.60[1.71; 3.95]125,28945229%NACoste (Controls unexposed, NOS) (Mixed indications), 2020 Miškov (Controls unexposed, disease free), 2016 Kilic (Controls unexposed NOS) (Mixed indications), 2014 3 unexposed, sick controlsunexposed, sick controls 2.31[0.57; 9.35]3937415%NAMiškov (Controls unexposed, sick), 2016 Kilic (Controls unexposed, sick) (Mixed indications), 2014 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.98[1.45; 2.69]3264530%NACoste (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020 Miškov (Controls exposed to Lamotrigine, sick), 2016 Arkilo, 2015 Kilic (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 40.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Veroniki a (NMA) (All indications) (Preterm birth)Veroniki a (NMA) (All indications) (Preterm birth) 1.93[0.88; 4.05]NA-Wwhatever (meta-analysis)Anyduring pregnancy (anytime or not specified)studies TTT-9 metaPregmetaPreg 2.38[1.79; 3.15]0%453----Coste (Controls unexposed, NOS) (Mixed indications), 2020 Miškov (Controls unexposed, sick), 2016 Arkilo, 2015 Kilic (Controls unexposed, sick) (Mixed indications), 2014 40.510.01.0